Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KTN1 antisense RNA 1 (KTN1-AS1)
- Target
- KTN1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
KTN1 antisense RNA 1 (KTN1-AS1) is a long non-coding RNA gene located on chromosome 14q22.3. It is frequently upregulated in multiple human tumors and is functionally implicated in promoting cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). KTN1-AS1’s tumorigenic mechanisms include acting as a molecular sponge for miRNAs (notably miR-23b and miR-505), modulating cancer signaling pathways such as the DEPDC1 axis, engaging in epigenetic regulation via recruitment of histone acetyltransferases like EP300, and forming chromatin-modifying complexes. KTN1-AS1 expression correlates with poor clinical outcomes and is under transcriptional control of oncogenic factors such as SOX2 and STAT1. KTN1-AS1 is explored as a biomarker and a potential therapeutic target in cancer, though no approved drugs specifically act on it to date
- Other names
- C14orf33MYCLo-3KTN1 antisense gene protein 1Putative uncharacterized protein KTN1-AS1
02
Mechanism of action
no approved drugs or well-characterized small molecules targeting KTN1-AS1; mechanism for hypothetical approaches would include antisense oligonucleotides or RNA-interference
03
Biological functions
Cell proliferationCell migrationCell invasionEpithelial-mesenchymal transition (EMT)Suppression of apoptosisRegulation of epigenetic modifications (histone acetylation)miRNA sponge (competes with miRNAs such as miR-23b, miR-505)
04
Disease associations
Cancer (pancreatic, bladder, non-small cell lung, esophageal squamous cell, hepatocellular, head and neck, colorectal)Prognostic biomarker (worse outcome/tumor progression)
05
Safety considerations
no direct safety concerns or therapeutic challenges reported based on existing studies; experimental therapeutic targeting of lncRNAs can have off-target or immune activation concerns, but none specific to KTN1-AS1 have been published
06
Biomarkers
High KTN1-AS1 expression as a marker of poor prognosis and cancer progressionAssociated expression markers: DEPDC1, MMP9, EMT markers (E-cadherin, N-cadherin, vimentin, MMP2)
Beyond the preview
Go deeper on KTN1 antisense RNA 1 (KTN1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KTN1 antisense RNA 1 (KTN1-AS1).